(May 2018) Researchers at the University of Colorado School of Medicine have identified a potential treatment target for patients with diastolic dysfunction, which is a heart relaxation abnormality.
According to a study published in the February 7 issue of the journal Science Translational Medicine, the researchers tested the effect of an investigational drug called givinostat in treating diastolic
HFpEF refers to cases where the heart can pump blood
Studying of the hearts of patients with diastolic dysfunction and HFpEF, the research team found that fibrosis, the commonly suspected culprit in these cases, is not the sole cause of diastolic dysfunction.
Instead, their findings indicated that there was a defect in the ability of the muscle cells of the heart to relax.
Mark Y. Jeong, MD, assistant professor of medicine, and Timothy A. McKinsey,
“These are exciting findings because we may be able to help patients with a form of heart failure that has been recalcitrant to standard-of-care therapies,” said McKinsey. “Givinostat is currently in clinical development for the treatment of muscular dystrophy. Our data suggest the possibility that givinostat could be ‘repurposed’ for the treatment of HFpEF.”
Further study is needed to determine whether it could be an effective treatment, said McKinsey, who is also director of the Consortium for Fibrosis Research & Translation (